BACKGROUND: Degenerative-like neuro-Langerhans cell histiocytosis (DN-LCH) is a rare complication of LCH marked by progressive cerebellar ataxia. No treatment has so far been shown to slow this progression. PROCEDURE: All-trans retinoic acid (ATRA) was administered orally at a dose of 45 mg/m(2) daily for 6 weeks and then 2 weeks every month for 1 year. The endpoints were clinical status at 1 year (assessed with rating scales for ataxia and disability), adverse effects, and changes in neurological abnormalities on MRI. RESULTS: Ten patients were studied. The treatment was well tolerated. All the patients were clinically stable at the end of the study. No MRI changes were noted. CONCLUSIONS: DN-LCH appeared to be stable during ATRA therapy, but further studies are required to appreciate the possible long-term benefits of ATRA. Copyright 2004 Wiley-Liss, Inc.
BACKGROUND: Degenerative-like neuro-Langerhans cell histiocytosis (DN-LCH) is a rare complication of LCH marked by progressive cerebellar ataxia. No treatment has so far been shown to slow this progression. PROCEDURE: All-trans retinoic acid (ATRA) was administered orally at a dose of 45 mg/m(2) daily for 6 weeks and then 2 weeks every month for 1 year. The endpoints were clinical status at 1 year (assessed with rating scales for ataxia and disability), adverse effects, and changes in neurological abnormalities on MRI. RESULTS: Ten patients were studied. The treatment was well tolerated. All the patients were clinically stable at the end of the study. No MRI changes were noted. CONCLUSIONS:DN-LCH appeared to be stable during ATRA therapy, but further studies are required to appreciate the possible long-term benefits of ATRA. Copyright 2004 Wiley-Liss, Inc.
Authors: N Martin-Duverneuil; A Idbaih; K Hoang-Xuan; J Donadieu; T Genereau; R Guillevin; J Chiras Journal: Eur Radiol Date: 2006-04-20 Impact factor: 5.315
Authors: Carl E Allen; Ricardo Flores; Ronald Rauch; Robert Dauser; Jeffrey C Murray; Diane Puccetti; David A Hsu; Paul Sondel; Maxine Hetherington; Stan Goldman; Kenneth L McClain Journal: Pediatr Blood Cancer Date: 2010-03 Impact factor: 3.167
Authors: Kenneth L McClain; Jennifer Picarsic; Rikhia Chakraborty; Daniel Zinn; Howard Lin; Harshal Abhyankar; Brooks Scull; Albert Shih; Karen Phaik Har Lim; Olive Eckstein; Joseph Lubega; Tricia L Peters; Walter Olea; Thomas Burke; Nabil Ahmed; M John Hicks; Brandon Tran; Jeremy Jones; Robert Dauser; Michael Jeng; Robert Baiocchi; Deborah Schiff; Stanton Goldman; Kenneth M Heym; Harry Wilson; Benjamin Carcamo; Ashish Kumar; Carlos Rodriguez-Galindo; Nicholas S Whipple; Patrick Campbell; Geoffrey Murdoch; Julia Kofler; Simon Heales; Marian Malone; Randy Woltjer; Joseph F Quinn; Paul Orchard; Michael C Kruer; Ronald Jaffe; Markus G Manz; Sergio A Lira; D Williams Parsons; Miriam Merad; Tsz-Kwong Man; Carl E Allen Journal: Cancer Date: 2018-04-06 Impact factor: 6.860
Authors: Michael Girschikofsky; Maurizio Arico; Diego Castillo; Anthony Chu; Claus Doberauer; Joachim Fichter; Julien Haroche; Gregory A Kaltsas; Polyzois Makras; Angelo V Marzano; Mathilde de Menthon; Oliver Micke; Emanuela Passoni; Heinrich M Seegenschmiedt; Abdellatif Tazi; Kenneth L McClain Journal: Orphanet J Rare Dis Date: 2013-05-14 Impact factor: 4.123